SCHEMBL3763908

SCHEMBL3763908

CC(C)(C)C(CNC(=O)c1ccc(N)cc1)NC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
MAPT P10636 1/20 0.50
HIF1A Q16665 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
SLC22A8 Q8TCC7 1/20 0.50
EPHX2 P34913 2/20 0.49
ESRRG P62508 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
LMNA P02545 4/20 0.43
SLC22A2 O15244 1/20 0.43
SLC22A1 O15245 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
ACHE P22303 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
MLYCD O95822 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21141800 0.88 LMNA (0.51) MAPTNPC1RAB9ALMNAALDH1A1
SCHEMBL13505994 0.88 LMNA (0.51) MAPTNPC1RAB9ALMNAALDH1A1
SCHEMBL3970923 0.87 RAB9A (0.48) KDM4EMAPTNPC1RAB9ALMNA
SCHEMBL3758450 0.86 ESRRG (0.51) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL13505949 0.75 POLB (0.50) NPC1RAB9ALMNAALDH1A1MLYCD
SCHEMBL21141804 0.75 POLB (0.50) NPC1RAB9ALMNAALDH1A1MLYCD
SCHEMBL21141808 0.75 POLB (0.50) NPC1RAB9ALMNAALDH1A1MLYCD
SCHEMBL19938018 0.75 EPHX2 (0.50) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL5940582 0.75 MLYCD (0.63) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL19210480 0.74 CYP2D6 (0.48) MAPTALDH1A1CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-8921544-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2014-12-30 US disclosed
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2014-09-18 US disclosed
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2013-04-25 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 KDM4E 718/4885MAPT 590/4885HIF1A 2026/4885
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 KDM4E 718/4885MAPT 590/4885HIF1A 2026/4885
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 KDM4E 718/4885MAPT 590/4885HIF1A 2026/4885
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 KDM4E 675/4885MAPT 570/4885HIF1A 1960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.